CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules

Background Anticancer therapies that target single signal transduction pathways often fail to prevent proliferation of cancer cells because of overlapping functions and cross-talk between different signaling pathways. Recent research has identified that balanced multi-component therapies might be more efficacious than highly specific single component therapies in certain cases. Ideally, synergistic combinations can provide 1) increased efficacy of the therapeutic effect 2) reduced toxicity as a result of decreased dosage providing equivalent or increased efficacy 3) the avoidance or delayed onset of drug resistance. Therefore, the interest in combinatorial drug discovery based on systems-oriented approaches has been increasing steadily in recent years. Methodology Here we describe the development of Combinatorial Drug Assembler (CDA), a genomics and bioinformatics system, whereby using gene expression profiling, multiple signaling pathways are targeted for combinatorial drug discovery. CDA performs expression pattern matching of signaling pathway components to compare genes expressed in an input cell line (or patient sample data), with expression patterns in cell lines treated with different small molecules. Then it detects best pattern matching combinatorial drug pairs across the input gene set-related signaling pathways to detect where gene expression patterns overlap and those predicted drug pairs could likely be applied as combination therapy. We carried out in vitro validations on non-small cell lung cancer cells and triple-negative breast cancer (TNBC) cells. We found two combinatorial drug pairs that showed synergistic effect on lung cancer cells. Furthermore, we also observed that halofantrine and vinblastine were synergistic on TNBC cells. Conclusions CDA provides a new way for rational drug combination. Together with phExplorer, CDA also provides functional insights into combinatorial drugs. CDA is freely available at http://cda.i-pharm.org.

[1]  S D Kemp,et al.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.

[2]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[3]  W. Moolenaar Bioactive lysophospholipids and their G protein-coupled receptors. , 1999, Experimental cell research.

[4]  J. Chun,et al.  Lysophosphatidic acid receptors. , 2000, Molecular pharmacology.

[5]  P. Goss,et al.  Estrogen and the risk of breast cancer. , 2001, The New England journal of medicine.

[6]  Ioannis Xenarios,et al.  DIP: The Database of Interacting Proteins: 2001 update , 2001, Nucleic Acids Res..

[7]  A. Ullrich,et al.  Molecular targets for breast cancer therapy and prevention , 2001, Nature Medicine.

[8]  G. Berx,et al.  The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression , 2001, Breast Cancer Research.

[9]  R. Bianco,et al.  Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. , 2001, Cancer research.

[10]  H. Nelson,et al.  Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. , 2001, The Journal of allergy and clinical immunology.

[11]  Eric K. Gupta,et al.  Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. , 2002, Heart disease.

[12]  M. Campiglio,et al.  Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  H. Kubinyi Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[14]  Adrian V. Lee,et al.  Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. , 2003, Cancer research.

[15]  Conrad Kunick,et al.  Alsterpaullone, a novel cyclin‐dependent kinase inhibitor, induces apoptosis by activation of caspase‐9 due to perturbation in mitochondrial membrane potential , 2003, Molecular carcinogenesis.

[16]  Adam J. Smith,et al.  The Database of Interacting Proteins: 2004 update , 2004, Nucleic Acids Res..

[17]  N. Campbell Genetic association database , 2004, Nature Reviews Genetics.

[18]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[19]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[20]  J. Stelling,et al.  Robustness of Cellular Functions , 2004, Cell.

[21]  Dan Xu,et al.  Specific Cleavage of Mcl-1 by Caspase-3 in Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis in Jurkat Leukemia T Cells* , 2005, Journal of Biological Chemistry.

[22]  M. Hung,et al.  EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization , 2006, Breast Cancer Research and Treatment.

[23]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[24]  Hiroshi Suzuki,et al.  Lysophosphatidic receptor, LPA3, is positively and negatively regulated by progesterone and estrogen in the mouse uterus. , 2006, Life sciences.

[25]  Keith T Flaherty,et al.  Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases , 2006, Molecular Cancer Therapeutics.

[26]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[27]  Qiang Wang,et al.  ErbB receptors: from oncogenes to targeted cancer therapies. , 2007, The Journal of clinical investigation.

[28]  Tatiana A. Tatusova,et al.  Entrez Gene: gene-centered information at NCBI , 2004, Nucleic Acids Res..

[29]  H. Kitano A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[30]  G. Hampton,et al.  Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole , 2007, Pharmacogenetics and genomics.

[31]  Martin Serrano,et al.  Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .

[32]  Todd R Golub,et al.  Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation , 2008, Proceedings of the National Academy of Sciences.

[33]  Soon-ja Kim,et al.  Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. , 2008, International journal of oncology.

[34]  R. García-Becerra,et al.  Regulation of LPA receptor function by estrogens. , 2008, Biochimica et biophysica acta.

[35]  Biyun Wang,et al.  Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. , 2008, Oral oncology.

[36]  C. Sander,et al.  Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.

[37]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[38]  Guanghui Hu,et al.  Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.

[39]  N Harbeck,et al.  Triple-negative breast cancer--current status and future directions. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Albert-László Barabási,et al.  A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..

[41]  Olivier Bouchaud,et al.  Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base , 2009, Malaria Journal.

[42]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[43]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[44]  Russ B. Altman,et al.  Pharmacogenomics and bioinformatics: PharmGKB. , 2010, Pharmacogenomics.

[45]  Jeremy E Purvis,et al.  Pairwise agonist scanning predicts cellular signaling responses to combinatorial stimuli , 2010, Nature Biotechnology.

[46]  S. Marsh,et al.  Irinotecan pharmacogenomics. , 2010, Pharmacogenomics.

[47]  U. Alon,et al.  Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses , 2010, Cell.

[48]  Ronald Simon,et al.  Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. , 2010, The American journal of pathology.

[49]  Yihong Ma,et al.  Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells , 2010, PloS one.

[50]  Xing-Ming Zhao,et al.  A systems biology approach to identify effective cocktail drugs , 2010, BMC Systems Biology.

[51]  A. Sapino,et al.  HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib , 2011, Breast Cancer Research and Treatment.

[52]  Lu Huang,et al.  Update of TTD: Therapeutic Target Database , 2009, Nucleic Acids Res..

[53]  Hua He,et al.  Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine , 2011, Brain Research Bulletin.

[54]  Lin He,et al.  Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome — Clozapine-Induced Agranulocytosis as a Case Study , 2011, PLoS Comput. Biol..

[55]  J. Croxtall,et al.  Fulvestrant , 2011, Drugs.

[56]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2011 , 2010, Nucleic Acids Res..

[57]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[58]  Livia Perfetto,et al.  MINT, the molecular interaction database: 2012 update , 2011, Nucleic Acids Res..